| LncRNA Information | ||||||
|---|---|---|---|---|---|---|
| ID | EL0366 | Name | EGOT | Aliases | EGO; NCRNA00190 | |
| Species | Homo sapiens | Chromosome | 3 | Start site | 4749192 | |
| End site | 4751590 | Chain | minus | Exon NO. | 2 | |
| Assembly | Ensembl Release 89 | Class | lincRNA | NCBI accession | NR_004428 | |
| Ensembl | ENSG00000235947 | Sequence | ||||
| Disease | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
| prostate cancer | microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. | prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) | down-regulated | N/A | Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. | 23728290 | Lnc2Cancer | ||
| breast cancer | qPCR etc. | breast cancer tissues, | down-regulated | expression | EGOT expression was lower in breast cancer compared with the adjacent noncancerous tissues, and low levels of EGOT expression were significantly correlated with larger tumor size, more lymph node metastasis, and higher Ki-67 expression. Moreover, patients with low levels of EGOT expression showed significantly worse prognosis for overall survival. Multivariate analysis suggested that low levels of EGOT were a poor independent prognostic predictor for breast cancer patients | 26159853 | Lnc2Cancer | ||